Literature DB >> 17058274

A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.

Luc E Gosselin1, Jacqueline E Williams, Kirkwood Personius, Gaspar A Farkas.   

Abstract

Skeletal muscles in mdx mice exhibit differential degrees of pathological changes and fibrosis. The purpose of this study was to examine differences in various indices of collagen metabolism in skeletal muscles with widely different functions and activity profiles in mdx mice, and to determine whether pirfenidone would attenuate the development of fibrosis. Mice in the pirfenidone group were orally fed pirfenidone (500 mg/kg) daily for 4 weeks. Marked differences were noted in hydroxyproline concentration between muscles, which could not be explained solely by the level of type I collagen and transforming growth factor-beta1 (TGF-beta1) mRNA. In normal mice, matrix metalloproteinase (MMP)-2 mRNA was significantly higher in the gastrocnemius than in the diaphragm or genioglossus muscles, suggesting that collagen degradation plays an important role in regulating collagen accretion in skeletal muscle. In mdx mice, the levels of both MMP-2 and MMP-9 mRNA were significantly elevated relative to control, although the response was muscle specific. Pirfenidone treatment resulted in a significant reduction in the level of hydroxyproline concentration across all muscles, although the effect was small. Results from this study reveal intrinsic dissimilarities in collagen metabolism between functionally different skeletal muscles. Moreover, the pharmacological use of pirfenidone may be beneficial in preventing fibrosis in muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17058274     DOI: 10.1002/mus.20681

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

Review 1.  Mechanical properties of respiratory muscles.

Authors:  Gary C Sieck; Leonardo F Ferreira; Michael B Reid; Carlos B Mantilla
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

Review 2.  Role of matrix metalloproteinases in skeletal muscle: migration, differentiation, regeneration and fibrosis.

Authors:  Xiaoping Chen; Yong Li
Journal:  Cell Adh Migr       Date:  2009-10-24       Impact factor: 3.405

Review 3.  Emerging drugs for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Jerry R Mendell
Journal:  Expert Opin Emerg Drugs       Date:  2012-06       Impact factor: 4.191

4.  Plantarflexion contracture in the mdx mouse.

Authors:  Michael W Garlich; Kristen A Baltgalvis; Jarrod A Call; Lisa L Dorsey; Dawn A Lowe
Journal:  Am J Phys Med Rehabil       Date:  2010-12       Impact factor: 2.159

Review 5.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

6.  NMDA receptor blockade maintains correlated motor neuron firing and delays synapse competition at developing neuromuscular junctions.

Authors:  Kirkwood E Personius; James L Karnes; Sara D Parker
Journal:  J Neurosci       Date:  2008-09-03       Impact factor: 6.167

7.  Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy.

Authors:  Hong Li; Ashwani Mittal; Denys Y Makonchuk; Shephali Bhatnagar; Ashok Kumar
Journal:  Hum Mol Genet       Date:  2009-04-28       Impact factor: 6.150

Review 8.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

9.  A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.

Authors:  K Huber; M Aichler; N Sun; A Buck; Z Li; I E Fernandez; S M Hauck; H Zitzelsberger; O Eickelberg; K P Janssen; U Keller; A Walch
Journal:  Histochem Cell Biol       Date:  2014-05-14       Impact factor: 4.304

10.  Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Authors:  Janelle M Spinazzola; Louis M Kunkel
Journal:  Expert Opin Orphan Drugs       Date:  2016-10-18       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.